Cholesterol Synthesis Inhibitors in Cholesterol Gallstone Disease

References

• Angelin B. Regulation of hepatic cholesterol metabolism in man. Ann Med 1991; 23: 177–80
   PubMed Web of Science ®Google Scholar
• Grundy S M. HMG-CoA reductase inhibitors for treatment of hypercholesterolaemia. N Engl J Med 1988; 319: 24–33
   PubMed Web of Science ®Google Scholar
• Maher V M, Thompson G R. HMG-CoA reductase inhibitors as lipid lowering agents: five years' experience with lovastatin and appraisal of simvastatin and pravastatin. Q J Med 1990; 74: 165–75
   PubMedGoogle Scholar
• Ditschuneit H R, Kuhn K, Ditschuneit H. Comparison of different HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1991; 40 Suppl 1: 27–32
   Google Scholar
• Kostis J B, Wilson A C, Tannenbaum A K, Pan H Y, Kuo P T. Long-term combination therapy of primary hypercholesterolaemia with pravastatin and cholestyramine. Circulation 1989; 80: 128
   PubMedGoogle Scholar
• Leiss O, von Bergmann K, Gnasso A, et al. Effect of gemflbrozil on biliary lipid metabolism in normolipidemic subjects. Metabolism 1985; 34: 74–82
   PubMed Web of Science ®Google Scholar
• Pertsemlidis D, Panveliwaila D, Ahrens E H, Jr. Effects of clofibrate and an estrogen-progestin combination on fasting biliary lipids and cholic acid kinetics in man. Gastroenterology 1974; 66: 565–73
   PubMed Web of Science ®Google Scholar
• The Coronary Drug Project Research Group. Coronary Drug Project. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231: 360–81
   PubMed Web of Science ®Google Scholar
• Duane W C, Hunninghake D B, Freeman M L, Pooler P A, Schlasner L, Gebhard R L. Simvastatin, a competitive inhibitor of HMG-CoA reductase lowers cholesterol saturation index of gallbladder bile. Hepatology 1988; 8: 1147–50
   PubMed Web of Science ®Google Scholar
• Hoogerbrugge-vd Linden N, De Rooy F WM, Jansen H, Van Blankenstein M. Effect of pravastatin on biliary lipid composition and bile synthesis in familial hypercholesterolaemia. Gut 1990; 31: 348–50
   PubMedGoogle Scholar
• Horiuchi I, Toshihide O, Tazuma S, Mizuno T, Takizawa I, Kajiyama G. Effects of pravastatin (CS 514) on biliary lipid metabolism in patients with hyperlipidaemia. Metabolism 1991; 40: 226–30
   PubMedGoogle Scholar
• Tazuma S, Ohya T, Teramen K, Horikawa K, Yamashita Y, Ochi H, et al. Effects of long-term treatment with low-dose pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on biliary lipid metastasibility in patients with hypercholesterolaemia [Abstract]. Hepatology 1993; 18: 308A
   Google Scholar
• Cipolla A, Mazzella G, Villanova N, Montagnani M, Salzetta A, Festi D, et al. Effect of simvastatin and UDCA on biliary lipid secretion and CSI during weight reduction [Abstract]. Hepatology 1993; S108
   Google Scholar
• Mazella G, Parini P, Festi D, Bazzoli F, Aldini R, Roda A, Tonelli D, et al. Effect of simvastatin, ursodeoxycholic acid and simvastatin plus ursodeoxycholic acid on biliary lipid secretion and cholic acid kinetics in non familial hypercholesterolaemia. Hepatology 1992; 15: 1072–8
   PubMedGoogle Scholar
• Logan G M, Duane W C. Lovastatin added to ursodeoxycholic acid further reduces biliary cholesterol saturation. Gastroenterology 1990; 98: 1572–6
   PubMedGoogle Scholar
• Holan K R, Holzbach H R, Hermann R E, Cooperman A M, Claffey W J. Nucleation time: a key factor in the pathogenesis of cholesterol gallstone disease. Gastroenterology 1979; 77: 611–7
   PubMed Web of Science ®Google Scholar
• Tazuma S, Hatsushika S, Aihara N, Sagawa H, Yamashita G, Sasaki M, Sasaki H, et al. Inhibitory effects of pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in prairie dogs. Digestion 1992; 51: 179–84
   PubMed Web of Science ®Google Scholar
• Saunders K D, Cates J A, Abedin M Z, Rege S R, Festekdjian S F, Howard W, Roslyn J J. Lovastatin inhibits gallstone formation in the cholesterol fed prairie dog. Ann Surg 1991; 214: 149–53
   PubMed Web of Science ®Google Scholar
• Saunders K D, Cates J A, Abedin M Z, Roslyn J J. Lovastatin and gallstone dissolution: a preliminary study. Surgery 1993; 113: 28–35
   PubMedGoogle Scholar
• Saunders K D, Cates J A, Abedin M Z, Roslyn J J. Lovastatin: a potential agent for gallstone dissolution [Abstract]. Gastroenterology 1993; 98: A260
   Google Scholar
• Smit J WA, van Erpecum K J, Stolk M FJ, Geerdink R A, Cluysenaer O JJ, Erkelens D W, Van Berge-Henegouwen G P. Successful dissolution of cholesterol gallstone during treatment with pravastatin. Gastroenterology 1992; 103: 1068–70
   PubMedGoogle Scholar
• Bligh E G, Dyer W J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959; 37: 911–7
   PubMedGoogle Scholar
• Turley S D, Dietschy J M. Reevaluation of the 3-hydroxy-steroid dehydrogenase assay for total bile acids in bile. J Lipid Res 1978; 19: 924–8
   PubMed Web of Science ®Google Scholar
• Carey M C. Critical tables for calculating the cholesterol saturation of native bile. J Lipid Res 1978; 19: 945–55
   PubMed Web of Science ®Google Scholar
• Bazzoli F, Mazella G, Zagari R M, Orsini M, Polimeni C, Novelli V, et al. HMG-CoA reductase inhibitors lower biliary cholesterol saturation but are ineffective cholesterol gallstone dissolving agents [Abstract]. Gastroenterology 1992; 102: A302
   Google Scholar
• Sedaghat A, Grundy S M. Cholesterol crystals and the formation of cholesterol gallstones. N Engl J Med 1980; 302: 1274–7
   PubMed Web of Science ®Google Scholar
• VanErpecum K J, VanBerge-Henegouwen G P, Stoelwinder B, Stolk M FJ, Eggink W F, Govaert W HA. Cholesterol and pigment gallstone disease: comparison of three bile tests for differentiation between the two stone types. Scand J Gastroenterol 1988; 23: 948–54
   PubMedGoogle Scholar
• Portincasa P, Di Ciaula A, Baldassarra G, Palmieri V, Gentile A, Cimmono A, Palasciano G. Gallbladder motor function in gallstone patients. Sonographic and 'in vitro' studies on the role of gallstones, smooth muscle function and gallbladder wall inflammation. J Hepatol 1994; 21: 430–40
   PubMed Web of Science ®Google Scholar
• Carey M C. Pathogenesis of gallstones. Am J Surgery 1993; 165: 410–9
   PubMed Web of Science ®Google Scholar
• Vickers S, Duncan C A, Vyas K P, et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG-CoA reductase. Drug Metab Dispos 1990; 18: 476–83
   PubMed Web of Science ®Google Scholar
• Tazuma S, Barnhart R L, Reeve L E, Tokumo H, Holzbach R T. Biliary secretion of organic anions in the dog: association with defined lipid particles. Am J Physiol 1988; 255: G745–51
   Google Scholar
• Reihner E, Rudling M, Stahlberg D, Berglund L, Ewerth S, Bjorkhem I, et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase on hepatic metabolism of cholesterol. N Engl J Med 1990; 323: 224–8
   PubMed Web of Science ®Google Scholar
• Smit J WA, VanErpecum K J, Renooij W, Stolk M FJ, Edgar P, Doornewaard H, VanBerge-Henegouwen G P. The effects of the HMG-CoA reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology 1995; 21: 1523–9
   PubMed Web of Science ®Google Scholar
• Ruben A Th, VanBerge-Henegouwen G P. A simple reverse phase high pressure liquid chromatographic determination of conjugated bile acids in serum and bile using a novel radial compression separation system. Clin Chim Acta 1982; 11: 941–50
   Google Scholar
• Kito M, Takamura H, Narita H, Urade R. A sensitive method for quantitative analysis of phospholipid molecular species by high performance liquid chromatography. J Biochem 1985; 98: 327–31
   PubMedGoogle Scholar
• Loria P, Bertolotti M, Cassinadri M T, Dilengite M A, Bozzoli M, Carubbi F, et al. Short-term effects of simvastatin on bile acid synthesis and bile lipid secretion in human subjects. Hepatology 1994; 19: 882–8
   PubMed Web of Science ®Google Scholar
• Lowe P J, Barnwell S G, Coleman R. Rapid kinetic analysis of the bile salt dependent secretion of phospholipid, cholesterol and a plasma membrane enzyme into bile. Biochem J 1984; 222: 631–7
   PubMed Web of Science ®Google Scholar
• Ulloa N, Garrido J, Nervi F. Ultracentrifugal isolation of vesicular carriers of biliary cholesterol in native human and rat bile. Hepatology 1987; 7: 235–44
   PubMedGoogle Scholar
• Davis R A, Highsmith W E, Malone McNeal M, Archambault-Schexnayder J, Kuan J CW. Bile acid synthesis by cultured rat hepatocytes: inhibition by mevinolin but not by bile acids. J Biol Chem 1983; 258: 4079–82
   PubMedGoogle Scholar
• Davis R A, Musso C A, Malone-McNeal M, Lattier G R, Hyde P M, Archambault-Schexnayder J, et al. Examination of bile acid negative feedback regulation in rats. J Lipid Res 1988; 29: 202–11
   PubMedGoogle Scholar
• Pandak W M, Heuman D M, Hylemon P B, Vlahcevic Z R. Regulation of bile acid synthesis IV. Interrelationship between cholesterol and bile acid biosynthesis path ways. J Lipid Res 1990; 31: 79–90
   PubMedGoogle Scholar
• Pandak W M, Vlahcevic Z R, Heuman D M, Hyleman P B. Regulation of bile acid synthesis. V. Inhibition of conversion of 7-dehydrocholesterol to cholesterol is associated with down regulation of cholesterol 7α hydroxylase activity and inhibition of bile acid synthesis. J Lipid Res 1990; 31: 2149–58
   PubMed Web of Science ®Google Scholar
• Kempen H JM, DeLange J, Van Vos-Holstein M PM, Van Wachem P, Havinga R, Vonk R J. Effect of ML-236B (compactin) on biliary excretion of bile salts and lipids, and on bile flow, in the rat. Biochim Biophys Acta 1984; 794: 435–43
   PubMedGoogle Scholar
• Mitchell J C, Stone B G, Logan G M, Duane W C. Role of cholesterol synthesis in regulation of bile acid synthesis and biliary cholesterol secretion in humans. J Lipid Res 1991; 32: 1143–9
   PubMed Web of Science ®Google Scholar
• Muraca M, Baggio G, Miconi L, Vilei M T, Martini S, Gabelli C, et al. Acute effects of HMG-CoA reductase inhibitors on biliary lipids in patients with interrupted enterohepatic circulation. Eur J Clin Invest 1991; 21: 204–8
   PubMedGoogle Scholar
• Smit J WA, VanErpecum K J, Portincasa P, Renooij W, Erkelens D W, VanBerge-Henegouwen G P. Effects of simvastatin and cholesyramine on bile lipid composition and gallbladder motility in patients with hypercholesterolaemia. Gut 1995; 37: 654–9
   PubMed Web of Science ®Google Scholar
• Heuman D M. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J Lipid Res 1989; 30: 719–30
   PubMed Web of Science ®Google Scholar
• Grundy S M, Ahrens E H, Jr, Salen G. Interruption of the enterohepatic circulation in bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med 1971; 78: 94–121
   PubMed Web of Science ®Google Scholar
• Garbutt J T, Kenney T J. Effect of cholestyramine on bile acid metabolism in normal man. J Clin Invest 1972; 51: 2781–9
   PubMed Web of Science ®Google Scholar
• Mitchell J C, Logan G M, Stone B G, Duane W C. Effects of lovastatin on biliary lipid secretion and bile acid metabolism in humans. J Lipid Res 1991; 32: 71–8
   PubMed Web of Science ®Google Scholar
• Mazella G, Cipolla A, Villanova N, Polimeni C, Cerre C, Montagnani M, et al. Ursodeoxycholic acid, differently from simvastatin, decreases cholesterol secretion in dieting obese subjects [Abstract]. Hepatology 1994; A941
   Google Scholar
• Nilsell K. Bile acid pool size and gallbladder storage capacity in gallstone disease. Scand J Gastroenterol 1990; 25: 389–94
   PubMed Web of Science ®Google Scholar
• Berr F, Pratschke E, Fisher S, Paumgartner G. Disorders of bile acid metabolism in cholesterol gallstone disease. J Clin Invest 1992; 90: 859–68
   PubMed Web of Science ®Google Scholar
• Jazrawi R P, Galatola G, Lanzini A, Northfield T C. Biliary lipid mass in health and in cholesterol gallstone disease. Eur J Gastroenterol Hepatol 1993; 5: 373–17
   Google Scholar
• VanErpecum K I, VanBerge-Henegouwen G P, Stolk M FJ, Hopman J PM, Jansen J BMJ, Lamers C BHW. Fasting gallbladder volume, postprandial emptying and cholecystokinin release in gallstone patients and normal subjects. J Hepatol 1992; 14: 194–202
   PubMedGoogle Scholar
• Everson G T, Braverman D Z, Johnson M L, Kem F, Jr. A critical evaluation of real time ultrasonography for study of gallbladder volume and contraction. Gastroenterology 1980; 79: 40–6
   PubMed Web of Science ®Google Scholar
• Stolk M FJ, VanErpecum K J, VanBerge-Henegouwen G P, Kesseiring O FHW, Hopman W PM. Ultrasonography for the study of gallbladder volume and contraction: comparison of sum and cylinders method with ellipsoid and area-length methods. Acta Radiologica 1990; 31 (Fasc 6): 591–6
   Google Scholar
• Ziegler K, Stünkel W. Tissue selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter. Biochim Biophys Acta 1992; 1139: 203–9
   PubMedGoogle Scholar
• Sonoda Y, Gotow T, Kuriyama M, Nakahara K, Arimura K, Osame M. Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors. Muscle Nerve 1994; 17: 891–7
   PubMed Web of Science ®Google Scholar
• Bastiaanse E ML, Atsma D E, Kuijpers M, Van Der Laarse A. Simvastatin-sodium delays cell death of anoxic cardiomyocytes by inhibition of the Na+/Ca2+ exchanger. FEBS Lett 1994; 343: 151–4
   PubMedGoogle Scholar
• Scott W A. Hydrophilicity and the differential pharmacology of pravastatin. Lipid Management. Round Table Series 1990; No 16: 17–25
   Google Scholar
• Singhvi S M, Pan H Y, Morrison R A. Disposition of pravastatin sodium, a tissue selective HMG-CoA-reductase inhibitor in healthy subjects. Br J Clin Pharmacol 1990; 29: 239–43
   PubMed Web of Science ®Google Scholar
• Everett D W, Chando T J, Didonato G C, Singhvi S M, Pan H Y, Weinstein S H. Biotransformation of pravastatin sodium in humans. Drug Metab Disp 1991; 19: 740–8
   PubMed Web of Science ®Google Scholar
• Pentikainen P J, Saraheimo M, Schwartz J I, et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992; 32: 136–40
   PubMed Web of Science ®Google Scholar
• Kibe A, Dudley M A, Halpern Z, Lynn M P, Breuer A C, Holzbach R T. Factors affecting cholesterol monohydrate crystal nucleation time in model systems of supersaturated bile. J Lipid Res 1985; 26: 1102–11
   PubMed Web of Science ®Google Scholar
• Groen A K, Ottenhof R, Jansen P LM, Van Marie J, Tytgat G NJ. Effect of cholesterol nucleation-promoting activity on cholesterol solubilization in model bile. J Lipid Res 1989; 30: 51–8
   PubMed Web of Science ®Google Scholar